Cryoablation of localized prostate cancer. Experience in 48 cases, PSA and biopsy results.
OBJECTIVE
As the first German center to perform perineal cryoablation of localized prostate cancer, we present our experience in a series of 48 consecutive patients.


METHODS
7 patients staged T1, 21 with T2 disease and 20 patients with T3 tumor were treated. 62.5% of the patients received neoadjuvant hormonal downsizing. Follow-up ranged from 4 to 27 months with a median of 15 +/- 5.7 months.


RESULTS
Positive control biopsies after 6 months were obtained in 0% of T1 tumors, 16.7% of T2 tumors and 26.7% of T3 tumors. Prostate-specific antigen persistence above 1 ng/ml was diagnosed in 14.3, 33.3, and 40%, respectively. Complications were acceptable. 22.9% of the patients had prolonged urinary retention, requiring transurethral resection in 5 patients (10.4%) to relieve obstruction. In 5 cases (10.4%) incontinence was found, in 2 of these patients mild urge incontinence declined over time, in 3 cases moderate to severe stress incontinence developed. Two of these patients were pretreated with radiotherapy. No fistulae were noted.


CONCLUSIONS
Cryoablation of the prostate is not a substitution for radical prostatectomy but enables the surgeon to perform a radical curative procedure in patients unfit for other radical forms of treatment or unwilling to undergo these. Long-term follow-up and prospective studies are necessary to define the clinical significance of this procedure.
Derakhshani
P
P
Department of Urology, University of Cologne, Germany. p.derakhshani@uni-koeln.de
Neubauer
S
S
Braun
M
M
Zumbé
J
J
Heidenreich
A
A
Engelmann
U
U
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D001707:Biopsy, Needle; D003452:Cryosurgery / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011183:Postoperative Complications; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen